Minta 2005 MLI

Methods	Trial design: Open RCT Trial dates: June 1993 to February 1994 and June 1994 to December 1994
Participants	Number of participants: 67 children aged three months to 15 years enrolled Inclusion criteria: Fever (core temperature ≥ 38 °C), positive blood smear for P. falciparum with ≥ 0.1% of parasitized erythrocytes, one major criterion or two minor criteria for severe malaria cases (WHO criteria) and parental consent Exclusion criteria: Patients with infection who had been treated within 24 hours with quinine or intramuscular injection was not eligible.
Interventions	1. Intramuscular artemether (Paluther) Loading dose of 3.2 mg/kg on admission (two times) Followed by 1.6 mg/kg once daily for four days 2. Intravenous quinine Loading dose of 20 mg/kg on admission Followed by 10 mg/kg every eight hours until oral drug administration was possible (10 mg/kg every eight hours)
Outcomes	Outcomes included in the review: Death Coma resolution time Fever clearance Parasite clearance Adverse events Outcomes not included in the review: Recrudescence
Notes	Location: Gabriel Touré's Hospital, Mali Transmission: Unknown Funding: Rhône‐Poulenc Rorer Doma (France)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Central randomization by clinical monitor.
Allocation concealment (selection bias)	Low risk	Opaque envelopes used to conceal allocation.
Blinding (performance bias and detection bias) Objective outcome: Death	Low risk	An open‐label trial is unlikely to bias an objective outcome like death. No blinding is described, and blinding would not be feasible.
Blinding (performance bias and detection bias) Subjective outcomes: Others	High risk	An open‐label trial.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses to follow‐up reported.
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting.
Other bias	Low risk	No other bias identified.